Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients

被引:0
|
作者
QIU Kui [1 ]
TIAN Hui [2 ]
WANG Wei [2 ]
HU Xiao-peng [2 ]
LI Xiao-bei [2 ]
GONG Li-li [3 ]
LUO Wei [3 ]
LIU Li-hong [3 ]
ZHANG Xiao-dong [2 ]
YIN Hang [2 ]
机构
[1] Department of Pharmacology Beijing Chao-Yang Hospital,Capital Medical University
[2] Kidney Transplantation Program,Department of Urology,Beijing Chao-Yang Hospital,Capital Medical University
[3] Department of Pharmacology,Beijing Chao-Yang Hospital,Capital Medical University
关键词
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Background Mycophenolic acid(MPA) as an anti-proliferative immune-suppressive agent is used in the majority of immunosuppressive regimens in solid organ transplantation.This study aimed to investigate the pharmacokinetic(PK) characteristics of enteric-coated mycophenolate sodium(EC-MPS) and area under the curve(AUC) from 0 to 12 hours with limited sampling strategies(LSSs) in Chinese renal transplant recipients. Methods This study was conducted in 10 Chinese renal transplant patients receiving living donor and treated with EC-MPS,cyclosporine,and corticosteroids.MPA concentrations were measured by enzyme multiplied immunoassay technique(EMIT).Whole 12-hour PK profiles were obtained on Day 4 after operation.LSSs with jackknife technique, multiple stepwise regression analysis,and Bland-Altman analysis were developed to estimate MPAAUC. Results The mean maximum plasma concentration,the mean time for it to reach peak(T;),and the mean MPA AUC were(11.38±2.49) mg/L,(4.85±3.32) hours,and(63.19±13.54) mgh·L;,respectively.Among the 10 profiles,MPA AUC of four patients was significantly higher than that of the other six patients,and the corresponding T;was significantly longer than that of the other six patients.No patient exhibited a second peak caused by enterohepatic recirculation.The best models were as follows-.27.46±0.94C;±3.24C;±2.81C;(r;=0.972),which was used to predict AUC of fast metabolizer with a mean prediction error(MPE) of -0.21%and a mean absolute prediction error(MAE) of 2.59%; 36.65±3.08C;±5.30C;-4.04C;(r;=0.992),which was used to predict AUC of slow metabolizer with a MPE of 0.58%and a MAE of 1.95%. Conclusions The PKs of EC-MPS had a high variability among Chinese renal transplant recipients.The preliminary PK data indicated the existence of slow and fast metabolizer.These findings may be associated with the enterohepatic recirculation.
引用
收藏
页码:4226 / 4232
相关论文
共 50 条
  • [11] Enteric-coated mycophenolate sodium
    Gabardi, S
    Tran, JL
    Clarkson, MR
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) : 1685 - 1693
  • [12] Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus
    Xu, Lu-yang
    Jiao, Zheng
    Liu, Fei-yan
    Qiu, Xiao-yan
    Ji, Li
    Zhang, Ming
    [J]. THERAPEUTIC DRUG MONITORING, 2018, 40 (05) : 572 - 580
  • [13] ENTERIC-COATED SODIUM MYCOPHENOLATE IN RENAL TRANSPLANT PATIENTS
    Rengel, Manuel
    Tana, Lorena
    Reque, Javier
    Quiroga-Gilis, Borja
    Panizo, Nayara
    Bucalo, Laura
    Abad, Soraya
    Vega, Almudena
    Verdalles, Ursula
    Verde, Eduardo
    [J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 111 - 111
  • [14] Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation
    Belliere, Julie
    Esposito, Laure
    Gandia, Peggy
    Duffas, Jean Pierre
    Sallusto, Federico
    Cardeau-Desangles, Isabelle
    Del Bello, Arnaud
    Rostaing, Lionel
    Kamar, Nassim
    [J]. ANNALS OF TRANSPLANTATION, 2014, 19 : 76 - 81
  • [15] Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN)
    Ranganathan, Dwarakanathan
    Abdul-Aziz, Mohd H.
    John, George T.
    McWhinney, Brett C.
    Fassett, Robert G.
    Healy, Helen
    Kubler, Paul
    Lim, Aaron
    Lipman, Jeffrey
    Purvey, Megan
    Roberts, Matthew
    Reyaldeen, Reza
    Ungerer, Jacobus
    Roberts, Jason A.
    [J]. THERAPEUTIC DRUG MONITORING, 2019, 41 (06) : 703 - 713
  • [16] Population pharmacokinetic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
    de Winter, B.
    van Gelder, T.
    Budde, K.
    Cattaneo, D.
    Tedesco-Silva, H.
    Neumann, I.
    Hilbrands, L.
    van Hest, R.
    Pescovitz, M.
    Mathot, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S61 - S61
  • [17] Enteric-coated mycophenolate sodium: Safe conversion from mycophenolate mofetil in maintenance renal transplant recipients
    Budde, K
    Glander, P
    Diekmann, F
    Dragun, D
    Waiser, J
    Fritsche, L
    Neumayer, HH
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (02) : 524S - 527S
  • [18] Enteric-coated mycophenolate sodium: an update
    Zhang, W.
    Ding, C.
    Zheng, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 : 1 - 3
  • [19] A Review of Enteric-coated Mycophenolate Sodium for Renal Transplant Immunosuppression
    Newbold, Nathan
    Riley, Brianna
    Hardinger, Karen
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 927 - 933
  • [20] Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients
    Massari, P
    Duro-Garcia, V
    Girón, F
    Hernández, E
    Juárez, F
    Castro, C
    Toledo, M
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 916 - 919